Abstract
Purpose of Review: Chimeric antigen receptor T-cell (CAR-T) therapy is a form of adoptive cellular therapy that has revolutionized the treatment landscape in hematologic malignancies, especially B-cell lymphomas. In this review, we will discuss some of the landmark data behind these therapies and then lay out our approach to utilizing this new therapy. Recent Findings: CD19-directed CAR-Ts are the most common type currently used in treatment of relapsed B-cell lymphoid neoplasms. There are currently three FDA-approved products: axicabtagene ciluecel and tisagenlecleucel for the treatment of relapsed/refractory large B-cell lymphoma and pediatric B-cell acute lymphocytic leukemia (tisagenlecleucel only) and brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma. These therapies are associated with distinctive acute toxicities such as cytokine release syndrome and neurotoxicity and chronic toxicities such as cytopenias and hypogammaglobulinemia. Summary: CAR-T therapy provides significant potential in the treatment of relapsed B-cell lymphomas despite current limitations. Several novel CAR cell designs are currently being studied in clinical trials which include tandem CAR-Ts, allogeneic CAR-Ts, and CAR-NK cells.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 32-39 |
| Number of pages | 8 |
| Journal | Current hematologic malignancy reports |
| Volume | 16 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 2021 |
Keywords
- B-cell lymphoma
- CAR-NK
- Chimeric antigen receptor T-cell (CAR-T)
- Cytokine release syndrome
- Novel CAR-T constructs
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research